aranidipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, nifedipine derivatives 234 86780-90-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aranidipine
  • sapresta
  • Molecular weight: 388.38
  • Formula: C19H20N2O7
  • CLOGP: 2.56
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 1
  • TPSA: 124.84
  • ALOGS: -4.54
  • ROTB: 8

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.435 Moderate 0.75
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.570 Moderate 0.75
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 53.333 10^-6 cm/s Moderate 0.75
dh-clint Dog hepatocyte intrinsic clearance 46.559 uL/min/10^6 cells Moderate 0.75
dppb Dog plasma protein binding (% unbound) 14.750 % Moderate 0.75
fcs-ppb Fetal calf serum protein binding (% unbound) 17.050 % Moderate 0.75
herg hERG pIC50 4.467 pIC50 Moderate 0.75
hh-clint Human hepatocyte intrinsic clearance 42.855 uL/min/10^6 cells Moderate 0.75
hlm-clint Human liver microsomal intrinsic clearance 188.365 uL/min/mg protein Moderate 0.75
hppb Human plasma protein binding (% unbound) 10.580 % Moderate 0.75
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK1,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PRKDC,STK33,TEK,TTK,ZAP70 37
kinase-selectivity-class AXL,BRAF,GRK2,PDK4,PIK3CD,STK33,TEK 7
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 2.138 High 0.82
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 4.775 Moderate 0.75
mh-clint Mouse hepatocyte intrinsic clearance 100.925 Moderate 0.75
mppb Mouse plasma protein binding (% unbound) 9.920 Moderate 0.75
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 16.982 Moderate 0.75
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 23.240 % Moderate 0.75
rat-kpuu-brain Rat brain Kpuu 0.035 % High 0.82
rh-clint Rat hepatocyte intrinsic clearance 171.002 uL/min/10^6 cells Moderate 0.75
rh-fuinc Rat hepatocyte fraction unbound in incubation 65.110 % Moderate 0.75
rppb Rat plasma protein binding (% unbound) 9.340 % Moderate 0.75
solubility-dd Solubility at pH 7.4 in DMSO 96.828 uM Moderate 0.75

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.5 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Voltage-gated L-type calcium channel Ion channel BLOCKER DRUG LABEL KEGG DRUG

External reference:

IDSource
D01562 KEGG_DRUG
C0165312 UMLSCUI
CHEBI:31232 CHEBI
CHEMBL2104030 ChEMBL_ID
DB09229 DRUGBANK_ID
C059427 MESH_SUPPLEMENTAL_RECORD_UI
2225 PUBCHEM_CID
11744 IUPHAR_LIGAND_ID
7071 INN_ID
4Y7UR6X2PO UNII

Pharmaceutical products:

None